Combining two drugs, i.e. difluoromethylornithine and sulindac, at low doses has been shown, for the first time, to provide both great efficacy and great safety for clinical colon cancer prevention.
Related Articles
Featured
Hereditary mutations in cancer: the use of panels and genetic counselling
Cover Story
Lynn Faulds Wood: tell it like it is
Senza categoria
Leave a Reply